An Economic Evaluation of Donepezil in Mild to Moderate Alzheimer’s Disease: Results of a 1-Year, Double-Blind, Randomized Trial

Publisher： Karger

E-ISSN： 1421-9824|15|1|44-54

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.15, Iss.1, 2002-12, pp. : 44-54

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Donepezil Treatment of Patients with Severe Alzheimer’s Disease in a Japanese Population: Results from a 24-Week, Double-Blind, Placebo-Controlled, Randomized Trial

By  

Dementia and Geriatric Cognitive Disorders, Vol. 25, Iss. 5, 2008-04 ,pp. : 399-407

Karger

Access to resources Recommend Favorite

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

By  

Dementia and Geriatric Cognitive Disorders, Vol. 30, Iss. 2, 2010-08 ,pp. : 131-146

Karger

Access to resources Recommend Favorite

A Double-Blind Placebo-Controlled Randomized Trial of Melissa officinalis Oil and Donepezil for the Treatment of Agitation in Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 31, Iss. 2, 2011-02 ,pp. : 158-164

Karger

Access to resources Recommend Favorite

Donepezil for the Treatment of Mild to Moderate Alzheimer’s Disease in France: The Economic Implications

By  

Dementia and Geriatric Cognitive Disorders, Vol. 17, Iss. 1-2, 2003-12 ,pp. : 5-13

Karger

Access to resources Recommend Favorite

The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1

By  

Dementia and Geriatric Cognitive Disorders, Vol. 10, Iss. 3, 1999-05 ,pp. : 237-244

Karger

Access to resources Recommend Favorite